Key Points
- Natera insider Solomon Moshkevich sold 15,160 shares for approximately $4.96 million at an average price of $326.89 under a pre-arranged Rule 10b5-1 plan to cover tax obligations. He retains 110,859 shares, although the sale reduced his position by 12.03%.
- Natera shares opened at $327.67, near their 52-week high of $343.18, with a market capitalization of about $47.23 billion. The company recently reported quarterly revenue of $752.75 million, up 37.7% year over year, and exceeded analysts’ EPS expectations.
- Analysts maintain a “Moderate Buy” consensus rating with an average price target of $319.38, while institutional investors own approximately 99.9% of Natera’s outstanding stock.
Natera, Inc. (NASDAQ:NTRA - Get Free Report) CEO Steven Chapman sold 1,698 shares of the stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $320.99, for a total value of $545,041.02. Following the sale, the chief executive officer directly owned 98,199 shares of the company's stock, valued at approximately $31,520,897.01. The trade was a 1.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Steven Leonard Chapman also recently made the following trade(s):
- On Monday, August 3rd, Steven Chapman sold 3,076 shares of Natera stock. The stock was sold at an average price of $266.39, for a total transaction of $819,415.64.
- On Tuesday, July 28th, Steven Chapman sold 3,580 shares of Natera stock. The stock was sold at an average price of $254.07, for a total value of $909,570.60.
- On Monday, July 27th, Steven Chapman sold 2,190 shares of Natera stock. The stock was sold at an average price of $260.49, for a total value of $570,473.10.
Natera Trading Up 0.8%
Natera stock opened at $327.67 on Friday. The company has a market cap of $47.23 billion, a P/E ratio of -240.93 and a beta of 1.54. Natera, Inc. has a 1-year low of $157.43 and a 1-year high of $343.18. The company has a fifty day simple moving average of $291.29 and a 200 day simple moving average of $237.00.
Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.02. The firm had revenue of $752.75 million for the quarter, compared to analyst estimates of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.The business's quarterly revenue was up 37.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.74) EPS. On average, equities research analysts forecast that Natera, Inc. will post -1.02 EPS for the current year.
Wall Street Analyst Weigh In
A number of research firms have issued reports on NTRA. Citigroup boosted their price objective on shares of Natera from $315.00 to $365.00 and gave the company a "buy" rating in a report on Thursday, August 13th. TD Cowen raised their price target on Natera from $325.00 to $340.00 and gave the stock a "buy" rating in a research report on Friday, August 7th. Evercore reaffirmed an "outperform" rating and set a $300.00 price objective on shares of Natera in a research report on Monday, July 6th. Wall Street Zen lowered shares of Natera from a "buy" rating to a "hold" rating in a report on Saturday, May 9th. Finally, Stephens boosted their target price on shares of Natera from $305.00 to $350.00 and gave the company an "overweight" rating in a research report on Wednesday, August 12th. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Natera has an average rating of "Moderate Buy" and an average price target of $319.38.
View Our Latest Stock Analysis on NTRA
Institutional Investors Weigh In On Natera
Several hedge funds have recently modified their holdings of the company. Integrated Wealth Concepts LLC raised its position in Natera by 6.6% in the first quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company's stock valued at $221,000 after purchasing an additional 96 shares during the last quarter. NewEdge Advisors LLC grew its holdings in shares of Natera by 68.3% during the first quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company's stock worth $644,000 after purchasing an additional 1,847 shares during the last quarter. Focus Partners Wealth increased its stake in shares of Natera by 8.6% in the first quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company's stock valued at $847,000 after buying an additional 474 shares during the period. Sivia Capital Partners LLC acquired a new position in shares of Natera in the second quarter valued at approximately $298,000. Finally, WINTON GROUP Ltd acquired a new position in shares of Natera in the second quarter valued at approximately $558,000. Institutional investors and hedge funds own 99.90% of the company's stock.
Natera Company Profile
(
Get Free Report)
Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.
Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
